We give you a written timeline estimate for your case before you commit.Ask about treatment
Glaucoma (open-angle glaucoma): US-approved treatments and how families in the Gulf can access them
A plain guide for families in the Gulf, checked against US FDA labels, US National Institutes of Health information, Gulf drug registers and published research on 17 October 2026.
Reviewed by the Reserve Meds clinical operations team on 17 October 2026.
Glaucoma: the short answer
The US FDA has approved three medicines covered on this page for glaucoma, each for a specific group of patients: Rhopressa, Rocklatan and Vyzulta. On 17 October 2026, three of them were on the Saudi or Abu Dhabi register, so ask your hospital about local supply first. Where a medicine is not registered, the treating hospital can ask the national regulator to import it for one named patient. Reserve Meds is a digital health company that helps with that process. We do not diagnose or prescribe.
- US FDA-approved medicines on this page: Rhopressa, Rocklatan and Vyzulta.
- Gulf registers (checked 17 October 2026): see each medicine below.
- Legal route: local supply where listed; otherwise a named-patient import request filed by the treating hospital.
- Price: Quote on request.
What is glaucoma?
Glaucoma is a group of eye diseases that can cause vision loss and blindness by damaging the optic nerve at the back of the eye. The most common type is open-angle glaucoma. Less common types include angle-closure glaucoma and congenital glaucoma.[1, 2]
At first, glaucoma usually has no symptoms, and half of people with glaucoma do not know they have it. Over time, vision is slowly lost, usually starting with side vision. The only way to find out is a comprehensive dilated eye exam.[1]
There is no cure, but early treatment can often stop the damage. Many people with glaucoma have high eye pressure, and treatments that lower eye pressure, most commonly prescription eye drops, help slow the disease.[1, 2]
Glaucoma in the Gulf
Gulf eye specialists have published on glaucoma, including a scoping review of glaucoma among the Saudi population (2023), a review of glaucoma in Oman (2006), and a case for a national screening program for primary congenital glaucoma in Saudi Arabia (2017).[3, 4, 5]
We checked every medicine on this page against the full SFDA drugs list and the Abu Dhabi Department of Health drug code list on 17 October 2026. 2 of 3 were listed in Saudi Arabia and 3 of 3 in Abu Dhabi. The result for each medicine is shown below. A listing does not mean every hospital stocks the medicine, and federal UAE, Kuwait, Qatar, Bahrain and Oman registers were not checked.[6, 7]
US FDA-approved medicines for glaucoma
Each medicine below is approved in the US for a specific group of patients. The wording summarizes the current US label. Your specialist decides whether any of them is right for the patient.
- Rhopressa (netarsudil)
US FDA-approved for reducing elevated eye pressure in open-angle glaucoma or ocular hypertension. It is a Rho kinase inhibitor eye drop.[8]
Current US label version: 20 January 2026. Gulf registers: Saudi Arabia (SFDA drugs list): not found. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[6, 7]
Country access guides: Saudi Arabia, UAE, India - Rocklatan (netarsudil and latanoprost)
US FDA-approved for reducing elevated eye pressure in open-angle glaucoma or ocular hypertension. It is an eye drop that combines netarsudil and latanoprost, sold as Roclanda outside the US.[9]
Current US label version: 27 August 2026. Gulf registers: Saudi Arabia (SFDA drugs list): listed as Roclanda. Abu Dhabi (DoH drug code list): listed as Roclanda. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[6, 7]
Country access guides: Saudi Arabia, UAE, India - Vyzulta (latanoprostene bunod)
US FDA-approved for reducing eye pressure in open-angle glaucoma or ocular hypertension. It is a prostaglandin analog eye drop.[10]
Current US label version: 27 February 2024. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[6, 7]
How families in the Gulf can access treatment
If the medicine is listed in your country. Ask your specialist and the hospital about local supply first. A listing does not mean every hospital stocks the medicine, but it is usually the fastest route, and you may not need us.
If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital confirms.[11, 12] Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital.
Who does what
- Your treating specialist decides whether a medicine is right for the patient and writes the medical letter.
- The hospital checks local supply, files any import request, and gives the treatment safely.
- The national regulator decides whether to approve the import of a medicine that is not registered.
- The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
- Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.
Documents you will usually need
- A letter from the treating specialist with the diagnosis, past treatments and why this medicine is being considered
- Reports that confirm the diagnosis, such as genetic, pathology, imaging or laboratory results, translated into English where needed
- Recent clinic notes and a list of current medicines
- For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
- Proof of the US FDA approval and the US prescribing information (we can supply these)
We give you a written timeline estimate for your case before you commit. The regulator, the hospital or treatment center and the manufacturer set their own timelines.
What treatment costs
Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.
How Reserve Meds helps
Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.
Ask us about treatment for glaucoma
Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.
Frequently asked questions
Is there an FDA-approved treatment for glaucoma?
Yes. The medicines on this page have US FDA approval for specific groups of patients: Rhopressa, Rocklatan and Vyzulta. The exact conditions are in each US label and are summarized above. Your specialist decides whether any of them fits.
Is Rhopressa available in Saudi Arabia or the UAE?
We checked on 17 October 2026. Saudi Arabia (SFDA drugs list): not found. Abu Dhabi (Department of Health drug code list): listed. A listing in Abu Dhabi does not show federal UAE status, which we could not verify. Your hospital confirms current supply.
How can a family in the Gulf get Rhopressa?
Ask the treating hospital about local supply first. If it is not available, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital.
How much does treatment cost?
Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.
Does Reserve Meds diagnose or prescribe?
No. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We do not diagnose, prescribe or decide what a regulator approves. Your specialist and hospital make the medical decisions.
Do these drops cure glaucoma?
No. There is no cure for glaucoma, but lowering eye pressure can slow or stop further damage. Regular checks with an eye specialist are essential.
Sources for the condition-specific answers: [1]
Sources
Accessed and checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital confirms the current position before anything is filed.
- National Eye Institute (NEI): Glaucoma
- MedlinePlus (US National Library of Medicine): Glaucoma
- Abuallut I, et al. Glaucoma among Saudi Arabian population: a scoping review. Int J Ophthalmol. 2023 (PubMed 38111936)
- Khandekarl R, et al. Glaucoma in oman: a review. J Glaucoma. 2006 (PubMed 16778653)
- Malik R, et al. Eradicating primary congenital glaucoma from Saudi Arabia: The case for a national screening program. Saudi J Ophthalmol. 2017 (PubMed 29234227)
- SFDA: Drugs List, public register (all 9,173 entries checked by brand name on 17 October 2026)
- Department of Health Abu Dhabi: drug code list Drugs.xlsx (release 26 September 2026, effective 2 October 2026)
- DailyMed: RHOPRESSA (netarsudil) US prescribing information, label version 20 January 2026
- DailyMed: ROCKLATAN (netarsudil and latanoprost) US prescribing information, label version 27 August 2026
- DailyMed: VYZULTA (latanoprostene bunod) US prescribing information, label version 27 February 2024
- SFDA: Special Access Program (SAP) guidance, version 1.0
- NHRA Bahrain: Circular No. (41) of 2020, procedures for importing non-registered medicines and pharmaceutical products
Related
- Diabetic retinopathy and diabetic macular edema
- Geographic atrophy
- Keratoconus
- Rhopressa: drug overview
- Rocklatan: drug overview
- Vyzulta: drug overview
- Named-patient access in the Gulf, explained
- US-approved medicines not yet registered in the Gulf
- Answers to common access questions
- Cross-border disclosures
- اقرأ هذه الصفحة بالعربية
- यह पृष्ठ हिंदी में पढ़ें
This page is general health information, not medical advice. It does not replace a consultation with your doctor.